Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer

N Agarwal, AW Hahn, DM Gill, JM Farnham… - JAMA …, 2017 - jamanetwork.com
Methods| We analyzed data from a prospectively maintained prostate cancer registry to
determine HSD3B1 genotype retrospectively in men treated with ADT for newly diagnosed
mH-SPC and to correlate this genotype with response to ADT. The study was approved by
the University of Utah institutional review board. All included patients have provided their
written informed consent. Genotyping was performed as described by Hearn at al. 1 The
primary end point was PFS on ADT. Progression was defined as 2 consecutive increases in …